Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Futibatinib - Taiho Oncology/Taiho Pharmaceutical

Drug Profile

Futibatinib - Taiho Oncology/Taiho Pharmaceutical

Alternative Names: LYTGOBI; TAS 120

Latest Information Update: 16 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiho Pharmaceutical
  • Developer Taiho Oncology; Taiho Pharmaceutical
  • Class Amines; Antineoplastics; Ketones; Phenyl ethers; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Biliary cancer
  • Registered Cholangiocarcinoma
  • Phase II Breast cancer; Gastric cancer; Lymphoid leukaemia; Myeloid leukaemia; Oesophageal cancer; Solid tumours; Urogenital cancer
  • Phase I/II Non-small cell lung cancer
  • Preclinical Rhabdomyosarcoma

Most Recent Events

  • 05 Dec 2023 Efficacy and adverse event data from a phase II trial in Breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
  • 20 Oct 2023 Taiho Pharmaceutical completes a phase Ib trial in Oesophageal cancer and non small cell lung cancer in Japan prior to October 2023 (jRCT2080224975)
  • 30 Sep 2023 Phase-I clinical trials in Solid tumours (Combination therapy with zimberelimab) in Japan prior to September 2023 (PO) (Otsuka Pharmaceutical pipeline, November 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top